Optimer's Dificid paves path for orals with CMS NTAP status
This article was originally published in Scrip
It took investors a few hours on 2 August to catch on to the significance of the win Optimer Pharmaceuticals scored with the US Centers for Medicare & Medicaid Services (CMS) in nabbing a new technology add-on payment (NTAP) designation on the firm's oral antibiotic Dificid (fidaxomicin), but by afternoon, the company's shares had climbed as high as 14.7%.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.